NCT01457495 - Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly | Biotech Hunter

Enrollment

312

Participants

Timeline

Start Date

September 30, 1998

Primary Completion Date

September 30, 1999

Study Completion Date

September 30, 1999

Conditions

Hepatitis BDiphtheriaHaemophilus Influenzae Type b (Hib)PoliomyelitisPertussisTetanus

Interventions

BIOLOGICAL

DTPa-HBV-IPV/Hib (Infanrix-hexa™)

3 doses administered intramuscularly into the right thigh at study month 0, 2 and 8

BIOLOGICAL

DTPa-IPV/Hib (Infanrix-IPV/Hib™)

3 doses administered intramuscularly into the right thigh at study month 0, 2 and 8

BIOLOGICAL

HBV (Engerix™-B)

3 doses administered intramuscularly into the left thigh at study month 0, 2 and 8